AL-S Pharma Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 2

AL-S Pharma General Information

Description

Developer of a human antibody designed to provide therapeutic benefits to patients suffering from amyotrophic lateral sclerosis. The company's antibody is directed against misfolded superoxide dismutase 1, enabling patients to lead a good life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Schlieren
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AL-S Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 07-Dec-2016 Completed Product Development
To view AL-S Pharma’s complete valuation and funding history, request access »

AL-S Pharma Executive Team (2)

Name Title Board Seat Contact Info
Michael Salzmann Ph.D Chief Executive Officer
Dirk Schimkat Chief Financial Officer
To view AL-S Pharma’s complete executive team members history, request access »

AL-S Pharma Board Members (5)

Name Representing Role Since
Guy Rouleau Ph.D AL-S Pharma Board Member 000 0000
Hubert Birner Ph.D TVM Capital Life Science Chairman 000 0000
Jan Grimm Ph.D Neurimmune Holding Board Member 000 0000
Marc Rivière MD TVM Capital Life Science Board Member 000 0000
Roger Nitsch MD AL-S Pharma Board Member 000 0000
To view AL-S Pharma’s complete board members history, request access »

AL-S Pharma Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Neurimmune Holding Corporation Minority 000 0000 000000 0
TVM Capital Life Science Venture Capital Minority 000 0000 000000 0
To view AL-S Pharma’s complete investors history, request access »